EQUASHIELD® Unveils CellSHIELD®: A Revolutionary Leap in Cell and Gene Therapy Production
EQUASHIELD®, a prominent name in healthcare innovation, has recently introduced the CellSHIELD® device, marking a significant advancement in the manufacturing processes of cell and gene therapies. This new device embodies EQUASHIELD's commitment to safety, efficiency, and innovation, and aims to set new standards in the biopharmaceutical industry.
Transforming Manufacturing Processes
The CellSHIELD® is a fully closed, sterile, and disposable system designed to address the critical challenges faced in cell and gene therapy manufacturing. It promises to enhance operational efficiency while ensuring the highest levels of safety and biocontainment. The closed design prevents contamination, allowing biopharma companies and contract development and manufacturing organizations (CDMOs) to scale their operations without compromising on product integrity.
One of the standout features of CellSHIELD® is its ability to reduce costs and optimize workflow by simplifying complex processes. This innovative system also supports critical applications, such as in-process testing and cell culture sampling, fluid transfer, and air removal, which are integral to maintaining precision in manufacturing.
Key Features and Advantages
EQUASHIELD® has equipped the CellSHIELD® with several key benefits:
- - Patient Safety and Quality: By maintaining a sterile and secure environment during manufacturing, the device upholds rigorous safety standards to protect patients.
- - Simplicity and Efficiency: Designed for ease of use, CellSHIELD® features processes that are easy to replicate, minimizing potential errors and enhancing overall productivity.
- - Minimal Training Requirements: The intuitive design of CellSHIELD® means that operators can get up to speed quickly, reducing the need for extensive training sessions.
- - Proven Expertise: Building on their legacy in Closed System Transfer Devices (CSTD), EQUASHIELD® brings trusted safety and containment principles into the realm of cell and gene therapy.
Insights from Industry Leaders
A cell therapy CDMO representative commented on their positive experiences with CellSHIELD®, noting, “The device has drastically minimized volume loss, consistently reporting under 0.1%. This is incomparable to previous systems we employed.”
Matt Stuckert, General Manager of EQUASHIELD®, emphasized the company's mission to innovate solutions for healthcare's toughest challenges. “CellSHIELD® represents a significant leap forward in cell and gene therapy manufacturing, empowering manufacturers to deliver essential therapies more safely and efficiently than before.”
Jason Dutcher, Director of Strategic Accounts, also praised the device’s ability to enhance scalability, an essential factor given the rising demand for therapies targeting genetic disorders.
Upcoming Showcase at Key Industry Events
EQUASHIELD® will take the opportunity to showcase CellSHIELD® at the forthcoming Cell and Gene Meeting on the Mesa, scheduled for October 6-8 in Phoenix, Arizona. Attendees will find an extensive display of how the CellSHIELD® is poised to revolutionize the landscape of cell and gene therapy manufacturing.
About EQUASHIELD®
As a global leader in healthcare technology, EQUASHIELD® is driven by a passion for innovation, safety, and efficacy. Known for its flagship Closed System Transfer Device (CSTD), which has become an industry standard, EQUASHIELD® continually seeks to develop transformative solutions that enhance operational safety and streamline workflows. The launch of CellSHIELD® is another step forward in the company's dedication to improving healthcare outcomes and facilitating the rapid advancement of medical therapies.
Media Contact
For further information about CellSHIELD®.
Email:
[email protected]
Website:
EQUASHIELD®
This revolutionary device could reshape the entire manufacturing landscape in the biopharmaceutical sector, clearly demonstrating EQUASHIELD®'s commitment to bring innovation and efficiency to healthcare.